4-甲烷磺酰氨基苯腈 | 36268-67-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲烷磺酰氨基苯腈
• 中文别名: 4-甲磺酰氨基苯腈；4-甲磺酰胺基苯腈
• 英文名称: 4-((methylsulfonyl)amino)benzonitrile
• 英文别名: N-(4-cyanobenzyl) methanesulfonamide；N-(4-cyanophenyl)methanesulfonamide；4-cyano methanesulphonanilide；4-mesylaminobenzonitrile；4-methanesulfonamino-1-benzonitrile；4-(Methanesulfonylamino)benzonitrile
• CAS: 36268-67-4
• 化学式: C₈H₈N₂O₂S
• mdl: MFCD00204724
• 分子量: 196.23
• InChiKey: BRDHOCVMWSXEHI-UHFFFAOYSA-N

物化性质

• 熔点：
  191-194 °C
• 沸点：
  365.5±44.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  常规情况下不会分解，没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 3276
• 海关编码：
  2935009090
• 包装等级：
  III
• 危险类别：
  6.1
• 安全说明：
  S36/37
• 危险性防范说明：
  P261,P280,P311
• 危险性描述：
  H302,H312,H331
• 储存条件：
  密封、阴凉、干燥、通风保存

SDS

Name:	4-(Methanesulfonylamino)benzonitrile Material Safety Data Sheet
Synonym:	None Known
CAS:	36268-67-4

Section 1 - Chemical Product MSDS Name:4-(Methanesulfonylamino)benzonitrile Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
36268-67-4	4-(Methanesulfonylamino)benzonitrile	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin. May be metabolized to cyanide which in turn acts by inhibiting cytochrome oxidase impairing cellular respiration.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
The toxicological properties of this substance have not been fully investigated. Metabolism may release cyanide, which may result in headache, dizziness, weakness, collapse, unconsciousness and possible death.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be metabolized to cyanide which in turns act by inhibiting cytochrome oxidase impairing cellular respiration.
Chronic:
Chronic exposure to cyanide solutions may lead to the development of a "cyanide" rash, characterized by itching, and by macular, papular, and vesicular eruptions, and may be accompanied by secondary infections. Exposure to small amounts of cyanide compounds over long periods of time is reported to cause loss of appetite, headache, weakness, nausea, dizziness, and symptoms of irritation of the upper respiratory tract and eyes.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Avoid contact with skin and eyes. Keep container tightly closed. Avoid ingestion and inhalation.
Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 36268-67-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: beige - fine
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 191 - 194 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8N2O2S
Molecular Weight: 196.1282

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong reducing agents, strong acids, strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 36268-67-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Methanesulfonylamino)benzonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 36268-67-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 36268-67-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 36268-67-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲烷磺酰氨基苯腈 在 aluminum nickel 作用下， 以 甲醇 、 甲醇盐酸 为溶剂， 生成 4-甲磺酰氨基苄胺盐酸盐
  参考文献：
  名称：

  Derivatized alkanolamines as cardiovascular agents

  摘要：

  以下结构式##STR1##的新型衍生烷醇胺被描述为有用的心血管药物。特别描述了它们作为表现出抗心律失常作用的心血管药物的有用性。所述的抗心律失常作用属于II类/III类结合型。还描述了含有这类化合物的药物配方。

  公开号：

  US05051423A1
• 作为产物：
  描述：

  对硝基苯甲腈 在 palladium on activated charcoal 吡啶 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 4-甲烷磺酰氨基苯腈
  参考文献：
  名称：

  Sklyarova, I. V.; Garabadzhiu, A. V.; Ginzburg, O. F., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, p. 578 - 582

  摘要：

  DOI：

文献信息

• Mild hypervalent iodine mediated oxidative nitration of N-aryl sulfonamides
  作者：Ulrich Kloeckner、Boris J. Nachtsheim

  DOI：10.1039/c4cc04738a

  日期：——

  An oxidative and acid-free method for the nitration of N-aryl sulfonamides has been developed using a combination of sodium nitrite as cheap and easy to handle NO2-source and the hypervalent iodine reagent PIFA as stoichiometric oxidant. Under very mild reaction conditions, the desired mononitrated aryl sulfonamides were isolated in up to 87% yield. This is the first example of an iodane-mediated oxidative nitration.

  已开发出一种无氧化剂和酸的N-芳基磺酰胺硝化方法，该方法采用廉价的亚硝酸钠作为易处理的NO2来源，以及高价碘试剂PIFA作为定量氧化剂。在非常温和的反应条件下，所期望的单硝基芳基磺酰胺以高达87%的产率被分离出来。这是首次报道碘烷介导的氧化硝化反应。
• Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors
  作者：Leslie J. Street、Raymond Baker、Jose L. Castro、Mark S. Chambers、Alexander R. Guiblin、Sarah C. Hobbs、Victor G. Matassa、Austin J. Reeve、Margaret S. Beer

  DOI：10.1021/jm00063a003

  日期：1993.5

  The selectivity of these compounds for 5-HT1D receptors over other serotonergic receptors is discussed. Sulfonamide 20t shows > or = 1000-fold selectivity for 5-HT1D over 5-HT2, 5-HT1C, and 5-HT3 receptors and 10-fold selectivity with respect to 5-HT1A receptors. The functional activity of this series of compounds is studied and demonstrates high 5-HT1D receptor potency and efficacy comparable to that

  描述了一系列新的5-（恶二唑基）色胺的合成和5-HT1D受体活性。研究了恶二唑3-取代基的修饰，连接链的长度（n）和胺取代基，并揭示了5-HT1D受体域中的大结合口袋。容纳恶二唑取代基如苄基而不会损失激动剂的效力或功效。在苯基或苄基间隔基团上引入极性官能团会导致亲和力和功能效能提高10倍。当杂环与吲哚偶联时，观察到最佳的5-HT1D活性，苄基磺酰胺20t和20u代表了一些已知的最有效的5-HT1D激动剂。杂环中的S取代O导致效能进一步提高。删除恶二唑N-2不会降低活性，建议在此位置仅需要一个H键受体。讨论了这些化合物对5-HT1D受体相对于其他血清素能受体的选择性。磺酰胺20t对5-HT1D的选择性比5-HT2、5-HT1C和5-HT3受体高> 1000倍，对5-HT1A受体的选择性高10倍。研究了该系列化合物的功能活性，并证明了与5-HT相当的5-HT1D受体效能和功效。
• Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists
  作者：Nannan Sun、Yafei Huang、Mingcheng Yu、Yunpeng Zhao、Ji-An Chen、Chenyu Zhu、Meiqi Song、Huimin Guo、Qiong Xie、Yonghui Wang

  DOI：10.1016/j.ejmech.2020.112536

  日期：2020.9

  GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered

  GSK805（1）是一种强效RORγt反向激动剂，但缺点1是它的低溶解度，从而导致在高剂量有限的吸收。我们已经探索了1的酰胺连接基，联芳基和芳基磺酰基部分的详细结构-活性关系，试图在保持RORγt活性的同时提高溶解度。结果，发现了一系列新颖的含羧基联芳基脲衍生物，作为具有改进的类药物性质的有效RORγt反向激动剂。化合物3i显示了强大的RORγt抑制活性和亚型选择性，在RORγFRET分析中的IC 50为63.8 nM，在基于细胞的RORγ-GAL4启动子报告子分析中为85 nM。合理的3i抑制活性在小鼠Th17细胞分化试验中也获得了抑制（在0.3μM时抑制76％）。此外，与1相比，3i在pH 7.4时具有大大改善的水溶解度，表现出体面的小鼠PK曲线，并在咪喹莫特诱导的牛皮癣小鼠模型中表现出一定的体内功效。
• Meta Selective C–H Borylation of Sterically Biased and Unbiased Substrates Directed by Electrostatic Interaction
  作者：Jagriti Chaturvedi、Chabush Haldar、Ranjana Bisht、Gajanan Pandey、Buddhadeb Chattopadhyay

  DOI：10.1021/jacs.1c01770

  日期：2021.5.26

  An electrostatically directed meta borylation of sterically biased and unbiased substrates is described. The borylation follows an electrostatic interaction between the partially positive and negative charges between the ligand and substrate. With this strategy, it has been demonstrated that a wide number of challenging substrates, especially 4-substituted substrates, can selectively be borylated at

  描述了空间偏压和无偏压底物的静电定向代谢硼化。硼酸化遵循配体和底物之间部分正电荷和负电荷之间的静电相互作用。使用这种策略，已经证明大量具有挑战性的底物，尤其是 4 取代底物，可以在间位选择性地硼酸化。此外，未取代的底物也表现出优异的间位选择性。该反应采用实验室稳定的配体并在较温和的温度下进行，无需合成庞大而复杂的配体/模板。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004011410A1

  公开（公告）日：2004-02-05

  Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  式(I)的化合物：其中变量基团如定义内；用于抑制11βHSD1。

表征谱图